GRAIL is trading 5.3% up at $77.88, with no clear company-specific catalyst identified for August 20, 2026.
- The latest material development is the FDA’s September 23 advisory committee meeting to review Galleri’s premarket approval application.
- Available coverage does not directly link that event to today’s gain.
- Biotech is broadly weaker, while major U.S. indexes are also lower, leaving the move unexplained.